Vilaprisan (BAY 1002670) + Vilaprisan Placebo + Microgynon + Microgynon Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clinical Trial ,Phase I

Conditions

Clinical Trial ,Phase I

Trial Timeline

Jul 17, 2017 → Jan 23, 2019

About Vilaprisan (BAY 1002670) + Vilaprisan Placebo + Microgynon + Microgynon Placebo

Vilaprisan (BAY 1002670) + Vilaprisan Placebo + Microgynon + Microgynon Placebo is a phase 1 stage product being developed by Bayer for Clinical Trial ,Phase I. The current trial status is completed. This product is registered under clinical trial identifier NCT03210246. Target conditions include Clinical Trial ,Phase I.

What happened to similar drugs?

1 of 4 similar drugs in Clinical Trial ,Phase I were approved

Approved (1) Terminated (1) Active (3)
PosaconazoleMerckApproved
🔄Lecanemab + PlaceboEisaiPhase 3
🔄Rebif®MerckPhase 3
🔄Cannabidiol (CBD) + PlaceboJazz PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03210246Phase 1Completed